| Ytd | -58.75% | |
| 1y | -80.51% |
| Open | 0.82 | Prev Close | 0.81 | Low | 0.80 | High | 0.84 | Mkt Cap | 39.46M |
| Vol | 408.49K | Avg Vol | 2.03M | EPS | -0.87 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.65 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 0.88 | 200-d Avg | 1.47 | 1yr Est | 0.00 |
FLNA News
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology comp
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-m
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's afte
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's af
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular
The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a tria
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a bi
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the anal
Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and an
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the anal
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufila